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ABSTRACT 
Background: 
Diagnosis of epithelial ovarian cancer (EOC) in young women has major implications 
including those to their reproductive potential. We evaluated depression, anxiety and 
body image in patients with stage I EOC treated with fertility sparing surgery (FSS) or 
radical surgery (RS). We also investigated fertility outcomes after FSS. 
 
Methods: 
A retrospective study was undertaken in which 62 patients completed questionnaires 
related to anxiety, depression, body image and fertility outcomes. Additional 
information on adjuvant therapy after FSS and RS and demographic details were 
abstracted from medical records. Both bi and multivariate regression models were used 
to assess the relationship between demographic, clinical and pathological results and 
scores for anxiety, depression and body image. 
 
Results: 
Thirty-nine patients underwent RS and the rest, FSS. The percentage of patients 
reporting elevated anxiety and depression (subscores ≥ 11) were 27 % and 5% 
respectively. The median (inter quartile range) score for body image scale (BIS) was 6 
(3-15). None of the demographic or clinical factors examined showed significant 
association with anxiety and BIS with the exception of ‘time since diagnosis’. For 
depression, post-menopausal status was the only independent predictor. Among those 
23 patients treated by FSS, 14 patients tried to conceive (7 successful), resulting in 7 
live births, one termination of pregnancy and one miscarriage. 
 
Conclusion: 
This study shows that psychological issues are common in women treated for stage I 
EOC. Reproduction after FSS is feasible and lead to the birth of healthy babies in about 
half of patients who wished to have another child. Further prospective studies with 
standardised instruments are required. 
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INTRODUCTION 
Approximately 23% of all stage I epithelial ovarian cancers (EOCs) occur in women 
who are younger than 40 years of age [1]. The standard treatment for apparent stage I 
EOC consists of a total abdominal hysterectomy (TAH), bilateral salpingo-
oophorectomy (BSO) and surgical staging plus adjuvant chemotherapy if indicated. 
However, radical treatment has major implications for patients’ childbearing potential. 
As an alternative for those patients who wish to preserve fertility, conservative surgery 
(fertility sparing surgery (FSS)) has been described previously demonstrating 
encouraging survival results [2-5].  
 
For patients, quality of life (QOL) is considered the second most important outcome of 
cancer treatment and patients should be informed about the likely impact on QOL when 
different treatment options are considered [6]. Across all stages of disease, nearly 30% 
of gynaecological cancer patients report psychological distress, and symptoms of 
depression, anxiety and hostility [7]. More recently, detriments to women’s body image 
through invasive surgery have been reported [8], as cancer and subsequent treatment 
have negative impact on self-esteem and perception of the body [9-11]. Although the 
description of ‘body image’ is not defined universally, the term encompasses body 
integrity, outer appearance, proper body functioning, and the ability to relate to others 
[12-15].  
 
To date, no studies investigated anxiety, depression, and body image among young 
women treated for stage I epithelial ovarian cancer (EOC) and demographic and clinical 
factors associated with better well-being. The purpose of this study therefore was to 
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evaluate factors associated with anxiety, depression and body image among young 
patients with stage I EOC who were treated by either FSS or RS. We also report on the 
reproductive outcomes of those patients treated by FSS.  
 
MATERIALS AND METHODS 
Subjects 
All patients with stage IA, IB and IC histologically confirmed invasive EOC, between 
18 and 45 years at time of diagnosis, who were treated at the Queensland Centre for 
Gynaecological Cancer (QCGC), Australia, from 01 April 1982 until 01 June 2004 were 
screened for eligibility to participate. Exclusion criteria included: (1) age at diagnosis > 
45 years; (2) deceased at time of the survey or lost to follow-up; (3) diagnosis of other 
ovarian tumour types (borderline or germ cell tumours); (4) prior hysterectomy; (5) 
previous or other concomitant malignancy; and (6) incomplete chart information 
regarding diagnosis, stage or surgical treatment. Tumours were staged according to the 
staging system of the International Federation of Gynaecology and Obstetrics (FIGO). 
All eligible survivors were sent standardised questionnaires (detailed below) and those 
who responded were included into this study. 
 
This study was approved by the local Human Research Ethics Committee (approval 
number 2005/013) of the Royal Brisbane and Women’s Hospital.  
 
Surgical and adjuvant treatment 
RS included total abdominal hysterectomy (TAH) with bilateral salpingo-oophorectomy 
(BSO), omentectomy and pelvic/para-aortic lymphadenectomy. Peritoneal washings, 
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diaphragmatic cytology and thorough exploration of the peritoneal cavity, including 
peritoneal biopsies were performed as part of the surgical staging procedure. FSS 
consisted of a unilateral salpingo-oophorectomy (SO), infracolic omentectomy, 
appendectomy, endometrial curettage, multiple peritoneal biopsies, peritoneal cytology, 
and pelvic and para-aortic lymphadenectomy. FSS was not performed in patients with 
bilateral EOC.  
 
Adjuvant chemotherapy was offered to all patients with incomplete surgical staging, 
bilateral ovarian involvement, clear-cell histological type, and higher grade tumours. 
The remainder of patients were offered adjuvant chemotherapy on an ad-hoc basis, at 
the discretion of the treating consultant. Surgical, pathological and chemotherapeutic 
details were abstracted from hospital medical records.  
 
Measures  
A standardised questionnaire package queried the following: (1) demographics; (2) 
reproductive function, fertility outcomes and offspring; (3) relationship status; and (4) 
the patient’s recall of her psychological functioning, in particular related to symptoms 
of anxiety and depression, prior to and after the diagnosis of ovarian cancer. 
Specifically, patients were asked whether they had ever or were taking medication to 
treat or prevent anxiety and or treat depression (yes/no), whether they thought to have 
suffered from anxiety/depression symptoms before or after their diagnosis and treatment 
for cancer (before/after/both/never) and whether they had sought counselling or therapy 
for anxiety or depression (before/after/both/never)  and/or whether they were currently 
receiving counselling or therapy for anxiety or depression (yes/no).  
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The Hospital Anxiety and Depression Scale (HADS) was used to assess the patients’ 
current (during the past week) level of psychological functioning. The HADS, 
developed by Zigmond and Snaith [16] in 1983, is an assessment scale to detect states 
of anxiety and depression in patients attending a hospital medical outpatient clinic, 
while it excludes potential somatic symptoms often associated with anxiety and 
depression but also common as a result of cancer treatment, such as fatigue. The HADS 
is subdivided into an anxiety subscale (HADS-A) and a depression subscale (HADS-D). 
Both subscales contain seven items, scored on a four-point scale from 0 to 3, with 
higher scores indicating greater levels of distress. The designers of the HADS advised 
to use a cut-off score of ≥ 11 to identify patients who have a high probability of 
suffering from a mood disorder, i.e. being a likely ‘case’[16].  
 
In addition to HADS, the Body Image Scale (BIS) questionnaire was completed by each 
patient. The BIS is a ten-item assessment scale designed to be applicable to patients 
with cancer of any site and any form of cancer treatment. The items cover affective, 
behavioural and cognitive issues, rated by the patient over the last week on a four-point 
scale from “not at all” to “very much”. The BIS score is the total ratings of each item, 
ranging from 0 to 30, with higher scores representing a worse body image. A cut-off 
score for body image disturbance is currently not available [8].  
 
The questionnaires were sent to all patients at the same time (cross-sectional), with 
patients’ time since diagnosis ranging from one to 23 years (median, 8.3 years). We also 
asked patients about their treatment outcomes after fertility sparing surgery. 
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Statistical analysis 
Statistical analyses were performed using Stata, version 10.1 (Statacorp, College 
Station, Texas, USA). Bivariate and multiple linear regression analyses were used to 
investigate associations between HADS and BIS scores with socio-demographic, and 
oncological characteristics. Age at diagnosis, time since diagnosis, educational level, 
occupational category, post-menopausal status, types of surgery, FIGO stages, 
histological tumour type and grade were the variables evaluated in bivariate analyses. 
All the variables associated at a significance level less than 0.2 in the bivariate analysis 
were entered simultaneously into subsequent multivariate models. Analyses were 
separately done for HADS-A, HADS-D and BIS scores. 
 
RESULTS 
Patients 
One-hundred-and-eight patients had had treatment for stage I EOC. Sixty four patients 
were eligible to participate in this study, and 62 (97%) patients completed the 
questionnaires. Forty-four patients met our exclusion criteria: 18 patients were lost to 
follow-up; 13 patients had incomplete information in their medical records; 9 patients 
had other ovarian tumour types; 4 patients had previous or concomitant malignancy. 
 
Socio-demographic and oncological characteristics of the patients are shown in Table 1. 
Thirty-nine patients underwent RS whereas twenty-three patients had FSS. Nearly 48% 
of patients had had university education. Fifty percent of patients considered their 
occupation as ‘skilled’. Forty-five (73.8%) patients were in a relationship at the time of 
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diagnosis. At time of the survey, 37 patients were in the same relationship as they were 
at the time of diagnosis, and 11 patients had another or new relationship.  
 
Anxiety and depression at the time of diagnosis 
Thirty-nine (62.9%) patients reported to have suffered from depression and or anxiety 
symptoms at the time of their diagnosis/treatment (Table 2). Thirty five (90%) of these 
patients had sought therapy for their anxiety and or depression. Twenty three patients 
had had counselling for depression and or anxiety. Twenty seven patients reported that 
they took medications for depression and 25 patients were prescribed medication for 
anxiety. At the time of the survey, 12 patients were on medication for 
depression/anxiety.  
 
Anxiety, Depression and Body Image at the time of the survey: The mean (SD) scores 
for HADS-A and HADS-D were 7.4(4.4) and 3.4(3.9) respectively. Overall, 27% of the 
patients had anxiety subscale score ≥ 11 (indicating elevated anxiety levels) and 5% of 
patients had depression subscale score ≥ 11 (indicating depression). The mean (SD) BIS 
score was 8.8 (7.6). 
 
Bivariate association of different socio-demographic and oncological variables with 
HADS-A, HADS-D and BIS scores are shown in Table 2. Time since diagnosis showed 
significant (p<0.02) inverse association with all these three scores. University education 
and certain histological tumour types also exhibited significant association with BIS 
scores. On multi-variate analyses, for HADS-A time since diagnosis was the only 
independent factor that remained significant decreasing reported anxiety scores by 0.21 
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points (95% CI 0.02 - 0.40; p = 0.02) for each year since diagnosis after adjusting for 
university education and histological type. For HADS-D, post-menopausal status 
increased the risk of depression by 3.4 points (95% CI = 0.54-6.21; p=0.02) after 
adjusting for time since diagnosis, histological type and grade. For BIS, time since 
diagnosis was the only independent predictor after adjusting for time since diagnosis, 
university education, skilled occupational status, histological type and grade, with 
women’s body image improving by 0.49 BIS points for each year since diagnosis (95% 
CI 0.15-0.83) p=0.005). 
 
Pregnancies after FSS 
Changes in menstrual pattern following initial therapy occurred in 11 (47.8%) of the 
FSS-patients: three patients were amenorrhoeic for less than six months; two patients 
for more than six months; and six patients experienced other changes in their menstrual 
pattern.  
Of the 23 patients who had FSS, 14 (60.9%) patients tried to conceive, for a median 
period of 12 months (range 2-312 months). Four (28.6%) patients used fertility drugs 
while trying to conceive: three with an assisted reproductive technology and one to 
assist ovulation. Finally, eight pregnancies were achieved by seven patients with seven 
healthy children (Table 3). Three of these patients had chemotherapy before they 
became pregnant; despite this, none of the babies had any congenital anomalies. 
 
Additional treatment 
Overall, sixteen patients (25.8%) required additional surgery after their initial 
therapeutic surgery, including RS after initial FSS, diagnostic procedures to screen for 
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recurrence and management of complications. A higher percentage of patients treated 
by FSS (n=9, 39.1%) required additional surgeries consisting of hysterectomy and or 
salpingo-oophorectomy. Of the nine FSS patients requiring additional surgery, three had 
become pregnant prior to their pelvic clearance.   
 
Twenty-six patients (41.9%) had chemotherapy as part of their treatment. Of these 
patients treated by chemotherapy, 18 (69.2%) patients reported long-term adverse 
effects. Adverse effects reported were paresthesia in hands and/or feet (n=9), muscular 
and/or joint pains (n=9), and other adverse effects (n=7). None of the patients developed 
renal failure. One patient required adjuvant pelvic radiotherapy and vaginal vault 
brachytherapy.  
 
DISCUSSION 
Young women diagnosed with EOC face several concerns that may impact on their 
mental health and quality of life, including threats to their reproductive potential. 
Indeed, the current study shows that more than 60% of women treated for stage I EOC 
recall being depressed and/or anxious at the time of their initial diagnosis and treatment, 
and 27% and 5%, respectively, still reported elevated anxiety or depression scores, up to 
23 years after surgery.  
 
Although the literature on QOL in patients with EOC is expanding, the evidence about 
psychosocial well-being after different surgical and adjuvant treatments is still sparse 
particularly for young women. Among the few studies reported to date, a variety of 
assessment instruments have been used to investigate these issues, and the studies did 
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not differentiate between patients diagnosed at early or late stages of EOC, making 
comparison of the literature complicated (Table 4). In addition, none of the previous 
studies investigated whether receiving FSS or RS influenced QOL outcomes among 
patients treated for early EOC. 
 
Our results indicate that ‘time since diagnosis’ is inversely related to anxiety and 
depression, and this result is consistent with those presented by Norton et al indicating 
that women’s mental well-being improves as they recover from a diagnosis of ovarian 
cancer [11]. Nevertheless, compared to the results from other studies which included 
patients with higher stage disease (Table 4), the percentage of stage I patients in our 
study with anxiety and depression at the time of diagnosis were relatively high. Possible 
explanations for this include population differences, recall bias, measurement and 
cultural differences. With regards to population,  younger patients have been reported to 
perceive cancer as an “out of order” experience compared to older patients and thus 
experience larger detriments to their QOL [17]. The higher incidence of anxiety 
compared to depression after treatment for EOC is in accordance with the literature [11, 
18-20].  
 
Our results indicate that the type of surgery patients received (RS or FSS), did not 
significantly influence quality of life outcomes including body image. This differs from 
Stead et al [9] who showed that BIS differed between patients who had different types 
of hysterectomy and Liavaag et al [20] who reported higher body image disturbance on 
average (mean BIS score =15.3, SD 6.0) among 189 EOC patients compared to our 
study. The long time since treatment was received on average by the patients in this 
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study and the early stage disease may have contributed to this finding [8, 12]. The only 
other study investigating body image in patients treated for EOC used a different 
outcome measure and reported that the patients had positive feelings about their face 
and hair, and neutral feelings about their body appearance, abdomen, sexual organs and 
weight [21].  
 
Reproductive outcomes 
In the current study almost two-thirds (14 of 23 patients) who underwent FSS tried to 
conceive. The actual pregnancy rate of 34.8% (8/23) is comparable with other studies 
investigating fertility outcomes after FSS, with most studies reporting pregnancy rates 
between 30 and 40% [2-5]. We observed a trend for FSS-patients to require more 
additional surgeries compared to RS treated patients. Demand from patients for RS after 
completing their family planning could explain most of this difference. Only one of the 
FSS-patients required additional surgery to investigate recurrence.  
 
Strengths and limitations 
This is the first study of depression, anxiety and body image scores in young patients 
with stage 1 EOC treated by FSS or RS. These results have to be interpreted with 
caution due to the retrospective nature of our study, the small sample size and non-
random allocation of patients to FSS and RS. Eighteen patients were lost to follow 
up/dead at the time of the survey, and these patients may have had worse outcomes than 
those who were contactable. Patients were treated up to 23 years prior to receiving our 
questionnaire, which is another limitation of this study (recall bias). In addition, 
treatment modalities might have improved including the introduction of platinum based 
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therapy, which make it possible that more recently treated patients have diverse 
treatment outcomes. Only one of the patients underwent laparoscopic procedure and 
advantages of laparoscopic versus open procedure could not be investigated.  
 
Conclusion 
Our study shows that symptoms of anxiety and depression are common in women 
treated for stage I epithelial ovarian cancer especially at the time of diagnosis and initial 
treatment. However, even after several years of treatment for stage I EOC, almost 27% 
of women report elevated levels of anxiety. Reproduction after FSS is feasible and leads 
to the birth of a healthy baby in more than 30% of patients. A prospective study which 
measures the trajectory of depression and anxiety depending on whether RS or FSS for 
early stage ovarian cancer is received could be important to further establish protective 
factors for psychological distress.  
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Tables 
T A B L E  1 .  C H A R A C T E R I S T I C S  O F  P A T I E N T S  I N  T H I S  S T U D Y  
 
Characteristics n (%) 
Age at diagnosis, years, mean (SD) 36.5 (7.5) 
Time since diagnosis, years, mean (SD) 10.0 (5.6) 
Gravidity, mean (SD) 2.6 (1.8) 
Post-menopausal 9 (15.5) 
Surgery 
           Fertility sparing surgery (FSS)         
           Radical Surgery 
 
23 (37.1) 
39 (62.9) 
Highest education level  
 Less than secondary school 17 (27.9) 
 Secondary school 14 (22.9) 
 < 3 years of studya 16 (26.2) 
 3-4 years of studyb 10 (16.4) 
 >4 years of studyc 4 (6.6) 
Occupation  
 Professionald 23 (37.1) 
 Clericale 8 (12.9) 
 Semi-skilledf 9 (14.5) 
 Home workg 15 (24.2) 
 Other 4 (6.5) 
FIGO stage  
 IA 38 (61.3) 
 IB 2 (3.2) 
 IC 22 (35.5) 
Histology  
 Mucinous 30 (48.4) 
 Serous 9 (14.5) 
 Endometrioid 17 (27.4) 
 Other 6 (9.7) 
Differentiation  
 Well 25 (40.3) 
 Moderately 15 (24.2) 
 Poorly 6 (9.7) 
  Unknown 16 (25.8) 
a. Completed trade certificate or qualification requiring less than 3 years of study. 
b. Academic or professional qualification requiring 3 or 4 years of university study. 
c. Academic or professional qualification requiring more than 4 years of university study. 
d. Professional or managerial. 
e. Clerical or sales.  
f. Semi-skilled includes semi-skilled and unskilled patients. 
g. Home work includes retired patients and patients with home duties. 
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T A B L E  2 .  B I V A R I A T E  A S S O C I A T I O N  O F  A N X I E T Y ,  D E P R E S S I O N  A N D  B O D Y  I M A G E  S C O R E S  W I T H  P A R T I C I P A N T  C H A R A C T E R I S T I C S  
  Anxiety Depression Body Image Scale 
Characteristics Coeff 95% CI p Coeff 95% CI p Coeff 95% CI p 
Age at diagnosis, years -0.04 -0.19 0.11 0.608 0.06 -0.07 0.20 0.339 -0.02 -0.28 0.24 0.872 
Time since diagnosis, years -0.24 -0.43 -0.05 0.014 -0.22 -0.39 -0.05 0.011 -0.56 -0.88 -0.24 0.001 
Fertility sparing surgery Vs radical surgery 0.56 -1.76 2.88 0.631 -0.37 -2.45 1.70 0.721 0.89 -3.17 4.94 0.663 
Attended university 1.83 -0.36 4.03 0.100 0.16 -1.85 2.17 0.875 5.57 1.92 9.22 0.003 
Skilled occupation -0.13 -2.37 2.12 0.909 -0.97 -2.96 1.02 0.335 3.19 -0.64 7.03 0.101 
Post-menopausal 0.13 -3.12 3.37 0.938 2.41 -0.43 5.25 0.094 3.14 -2.46 8.73 0.266 
FIGO 1B and 1C (1A as reference) -0.42 -1.56 0.73 0.469 -0.27 -1.29 0.76 0.606 0.27 -1.74 2.28 0.787 
             
Histology (Mucinous as reference)             
Endometrioid Vs Mucinous -1.89 -4.48 0.70 0.149 -0.36 -2.74 2.01 0.76 -2.01 -6.42 2.41 0.367 
Serous Vs Mucinous 2.06 -1.18 5.29 0.209 1.29 -1.68 4.26 0.389 4.70 -0.82 10.22 0.094 
Others Vs Mucinous -2.33 -6.14 1.48 0.225 -2.43 -5.93 1.07 0.169 -6.63 -13.13 -0.13 0.046 
Differentiation (Well differentiated as reference)             
Moderately differentiated Vs Well diff 1.29 -1.54 4.13 0.365 -0.72 -3.28 1.84 0.575 -1.63 -6.63 3.37 0.518 
Poorly differentiated Vs Well diff -1.31 -5.26 2.64 0.511 -1.32 -4.88 2.24 0.461 0.51 -6.46 7.47 0.885 
Unknown differentiation Vs Well diff -1.70 -4.48 1.08 0.226 -2.20 -4.70 0.31 0.085 -3.97 -8.88 0.93 0.110 
FIGO: International Federation of Gynaecology and Obstetrics 
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T A B L E  3 .  C H A R A C T E R I S T I C S  O F  T H E  C O N C E P T I O N S  A F T E R  F S S   
( 7  O F  14  P A T I E N T S  W H O  T R I E D  T O  C O N C E I V E )  
Pt Conception 
(n=8) 
Outcome Term 
(weeks) 
Fertility 
treatment 
Chemotherapy Congenital  
anomalies 
1 1 Single baby  40 No Yes No 
2 1 Single baby 40  No Yes No 
3 1 TOP 10 No No No 
4 
1 Single baby 40 No No No 
2 Single baby 40 No No No 
5 1 Single baby 40 No No No 
6 1 Miscarriage 12 Yes No No 
7 1 Twins 28 No Yes No 
FSS = fertility sparing surgery; Pt = patient; TOP = termination of pregnancy. 
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T A B L E  4 .  R E V I E W  O F  T H E  L I T E R A T U R E  F O R  D E P R E S S I O N  A N D  A N X I E T Y  I N  O V A R I A N  C A N C E R  
Author Population N Stage I (%) Used Measures Results 
    Depression Anxiety  
Kornblith [19] 
1995 
Ovarian cancer patients 
(74% hospitalized) 
151 14a 
 
MSAS,  
MHI-38 
MSAS, 
 MHI-38 
MSAS: > 1/3 of patients had moderate to severe symptoms of 
anxiety and depression 
MHI: 17% highly depressed, 22% highly anxious 
       
Bodurka [22] 
2000 
EOC patients 
(94.3% outpatient) 
246 26a 
 
CES-D STAI 21% met the cut-off criteria for clinical evaluation of depression 
29% scored above the 75th percentile for anxiety 
       
Wenzel [23] 
2002 
> 5 years stage I and II 
ovarian cancer survivors 
49 77.6 CES-D  6% met cut-off criteria for significant depressive symptoms 
       
Hipkins [18] 
2004 
EOC patients at the end of 
chemotherapy and with 3 
months follow-up 
63 22 HADS HADS Significant increase in anxiety scores ≥ 8 (38% to 47%) and 
reduction in depression scores ≥ 8 (33% to 19%) over follow-up 
time 
       
Norton [11] 
2004 
Ovarian cancer patients 143 14 BDI,  
MHI-18 
MHI-18 BDI: 20% had moderate to severe depressive symptoms 
MHI: 23% had moderate to high distress, with significantly higher 
mean levels of anxiety than depressive symptoms 
       
Parker [24] 
2006 
EOC patients starting 
chemotherapy 
126 8 CES-D STAI 25% met cut-off criteria for significant depressive symptoms 
Mean anxiety score was at the 69th percentile compared with 
normative samples 
       
De Moor [25] 
2006 
EOC patients starting 
chemotherapy 
90 8 
 
CES-D STAI Mean depression score 11.0 (SD 4.95)b, mean anxiety score 36.11 
(SD 8.61)b, (no cut-off scores mentioned) 
       
Liavaag [20] 
2007 
EOC patients with > 18 
months survival versus 
controls 
189 43 HADS HADS Mean depression score 3.1, mean anxiety score 5.6 
Anxiety levels were significantly higher and depression levels 
lower than in controls 
N = number of patients included in the study; EOC = epithelial ovarian cancer; SD = standard deviation.  
MSAS = Memorial Symptom Assessment Scale; MHI = Mental Health Inventory; CES-D = Centre for Epidemiologic Studies-Depression scale; STAI = Spielberger State and Trait Anxiety Inventory for 
Adults; HADS = Hospital Anxiety and Depression Scale; BDI = Beck Depression Inventory. 
a. Includes stage I and II. b. Results presented for stage I and II together. Stage I and II make up 15% of the total number of patients.  
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